Cramer Says Pfizer (PFE) Should Buy Allergan (AGN)
More News related to AGN
- Spectrum Pharma (SPPI) To Collaborate with Nippon Kayaku to Develop and Commercialize Apaziquone in Asia
- The Lowe Law Firm Files Suit over Alleged Botox Overdose
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
- Allergan (AGN) Posts Q3 EPS of $1.13, Topping Street; Guides FY09
- Don't Miss Out! The Registration Period for the 2010 IR Global Rankings Ends TOMORROW!
More News related to MNT
- Allergan (AGN) Up On Takeover Rumors
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
- Johnson & Johnson (JNJ) Completes Tender Offer of Mentor Corp (MNT)
- Johnson & Johnson (JNJ) Receives Clearance for Tender to Buy Mentor; Sees Deal Dilutive to '09 EPS by $0.03-$0.05
- S&P Announces Changes to US Indices: LSTR for PSUN, ASEI for LSTR, BLUD for FBN, AVAV for BLUD, BRLI for MNT
More News related to PFE
- Paladin Reports Record Third Quarter 2009 Financial Results
- Pfizer Merger to Shut Down Six R&D Sites, Resulting in 2,000 Layoffs, an Industrial Info News Alert
- Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
- Former Pfizer Global R&D President John LaMattina Joins PureTech Ventures as Senior Partner; PureTech Announces Partner Promotions
- Monsanto (MON) Agrees to Acquire Pfizer's (PFE) Chesterfield Village Research Center for $435M
More News related to Insiders' Blog
- Brazil Suffers Massive Power Outage, Yet Shares Little Affected (EWZ)
- Palm (PALM) Shares Rallying as Analysts Gaining Confidence
- Wal-Mart Giving Away a $100 Gift Card With Purchase of RIM (RIMM) BlackBerry
- One In Five Consumers Plan to Buy a Fragrance This Holiday Season - NPD (PERF, PARL)
- Citigroup (C) Kelly Making Comments At Banking Conference: "Balance Sheet is Very Liquid"
On Mad Money tonight, Jim Cramer said Pfizer (NYSE: PFE) should really take a strong look at buying Allergan (NYSE: AGN). Cramer thinks this is a smart play similar to Johnson & Johnson buying out Mentor Corporation (NYSE: MNT) earlier in the week.
Both Allergan and Mentor produce products that are used in cosmetic surgeries.
Additionally, Cramer liked that Allergan has a strong growth rate, whereas Pfizer has no growth. Therefore, if Pfizer makes a play for Allergan, it would get that much needed growth the Street covets.
In today's trading, Allergan closed at $36.20 and currently in the after-hours it is at $35.18.
Allergan, Inc. is a multi-specialty healthcare company focused on developing and commercializing pharmaceuticals, biologics and medical devices.
Sign up at EasyStockAlerts.com To Be Alerted To Your Stock News!
Related Categories
Insiders' BlogTrader Talk
Stocks Mentioned
-0.45
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
